THRX Share Price

Open 9.81 Change Price %
High 10.25 1 Day 0.04 0.41
Low 9.59 1 Week 0.00 0.00
Close 9.81 1 Month 0.00 0.00
Volume 668805 1 Year 0.00 0.00
52 Week High 44.62
52 Week Low 26.60
THRX Important Levels
Resistance 2 10.42
Resistance 1 10.17
Pivot 9.88
Support 1 9.45
Support 2 9.20
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Theravance, Inc. (NASDAQ: THRX)

THRX Technical Analysis 1.5
As on 8th Jan 2016 THRX Share Price closed @ 9.81 and we RECOMMEND Sell for LONG-TERM with Stoploss of 13.78 & Buy for SHORT-TERM with Stoploss of 9.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
THRX Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
THRX Other Details
Segment EQ
Market Capital 2123501440.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.theravance.com
THRX Address
THRX
901 Gateway Boulevard
South San Francisco, CA 94080
United States
Phone: 650-808-6000
Interactive Technical Analysis Chart Theravance, Inc. ( THRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Theravance, Inc.
THRX Business Profile
Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its programs include RELVAR or BREO (fluticasone furoate/vilanterol), ANORO (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid Receptor Antagonist program. Fluticasone Furoate/Vilanterol (FF/VI) is an investigational once-daily inhaled ICS/ LABA combination treatment, comprising fluticasone furoate (FF) and vilanterol (VI), for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) and patients with asthma.